The SuperNAT demonstrates 48.6% higher sensitivity than conventional ELISA, with its clinical validation data accepted for poster at ASN Kidney Week 2025. WASHINGTON, DC, UNITED STATES, December 25, 2025 / EINPresswire.com / -- AlloDx , a pioneer in precision renal diagnostics from Shanghai, announced that clinical validation data for its proprietary SuperNAT (Super Nephrin Antibody Trap) technology platform had been accepted for poster presentation at the American Society of Nephrology's Kidney

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. The TABOSUN® and TYVYT® combination therapy significantly improved pathological complete response (pCR) rates and enabled most patients to avoid the burden of postoperative adjuvant chemotherapy. This therapy is the first and only dual-

A new study suggests that dementia may be driven in part by faulty blood flow in the brain. Researchers found that losing a key lipid causes blood vessels to become overactive, disrupting circulation and starving brain tissue. When the missing molecule was restored, normal blood flow returned. This discovery opens the door to new treatments aimed at fixing vascular problems in dementia.A potential new way to treat reduced brain blood flow and certain forms of dementia is beginning to emerge. Sci

A major evolutionary theory says most genetic changes don’t really matter, but new evidence suggests that’s not true. Researchers found that helpful mutations happen surprisingly often. The twist is that changing environments prevent these mutations from spreading widely before they become useless or harmful. Evolution, it turns out, is less about reaching perfection and more about endlessly chasing a moving target.For decades, many evolutionary biologists have believed that most genetic changes

Tramadol, a popular opioid often seen as a “safer” painkiller, may not live up to its reputation. A large analysis of clinical trials found that while it does reduce chronic pain, the relief is modest—so small that many patients likely wouldn’t notice much real-world benefit. At the same time, tramadol was linked to a significantly higher risk of serious side effects, especially heart-related problems like chest pain and heart failure, along with common issues such as nausea, dizziness, and slee

NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder (MDD). The study did not meet its primary endpoint, a reduction of depressive symptoms as mea

DUBLIN--(BUSINESS WIRE)--The "Clinical Trial Supply & Logistics Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The clinical trial supply & logistics market is seeing transformative shifts driven by regulatory complexity, operational advances, and increased demand for patient-centric models. Senior leaders face evolving pressures that demand robust strategies to manage sourcing, distribution, compliance, and innovation. Market Snapshot: Clinical Tr

TX, UNITED STATES, December 24, 2025 / EINPresswire.com / -- Brown, LLC , a nationally recognized whistleblower and Medicaid and Medicare fraud law firm, announces a $41.5 million settlement with Pfizer Inc. and Tris Pharma, Inc. resolving claims brought under the Texas Health Care Program Fraud Prevention Act in the 71st Judicial District Court of Harrison County, Texas. The settlement addresses allegations that the companies improperly obtained Medicaid reimbursements for the ADHD medication Q

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD). Throughout 2025, Clearmind achieved cri

SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, for oral presentation at the upcoming European Association of Urolo